AREVA Med: New Research Agreement with University of Cincinnati

Date:

AREVA subsidiary AREVA Med and the University of Cincinnati, Ohio, announced today that they have signed a research agreement to develop a new treatment to combat cancer. Under the agreement, AREVA will provide the medical-grade isotope Lead-212 to the university for researchers to conduct studies on alpha radio-immunotherapy which uses this isotope to treat prostate cancer.

AREVA Med

Already the use of AREVA’s medical-grade Lead-212 isotope has proved promising in research efforts. Over the past few years, AREVA and its partners have demonstrated significant benefits by using Lead-212 as an innovative type of nuclear medicine to combat cancer.

Because Lead-212 is a rare isotope, AREVA has utilized is experience in radiochemistry and nuclear engineering to develop a new process to produce Lead-212 so that it can be used for this type of research.

More information on the AREVA Med project is available here or read the press release.

Share this post

Share post:

Subscribe

Popular

More like this
Related